ATE439141T1 - Zusammensetzungen basierend auf midkine zur behandlung von chronischen ischämienreperfusionsschäden - Google Patents

Zusammensetzungen basierend auf midkine zur behandlung von chronischen ischämienreperfusionsschäden

Info

Publication number
ATE439141T1
ATE439141T1 AT05814479T AT05814479T ATE439141T1 AT E439141 T1 ATE439141 T1 AT E439141T1 AT 05814479 T AT05814479 T AT 05814479T AT 05814479 T AT05814479 T AT 05814479T AT E439141 T1 ATE439141 T1 AT E439141T1
Authority
AT
Austria
Prior art keywords
midkine
treatment
reperfusion injury
compositions based
chronic ischemia
Prior art date
Application number
AT05814479T
Other languages
English (en)
Inventor
Mitsuru Horiba
Itsuo Kodama
Takashi Muramatsu
Kenji Kadomatsu
Original Assignee
Cell Signals Inc
Univ Nagoya Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signals Inc, Univ Nagoya Nat Univ Corp filed Critical Cell Signals Inc
Application granted granted Critical
Publication of ATE439141T1 publication Critical patent/ATE439141T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT05814479T 2004-12-06 2005-12-06 Zusammensetzungen basierend auf midkine zur behandlung von chronischen ischämienreperfusionsschäden ATE439141T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004352513 2004-12-06
JP2005187420A JP4791770B2 (ja) 2004-12-06 2005-06-27 心筋障害又は心不全の治療もしくは予防組成物
PCT/JP2005/022354 WO2006062087A1 (ja) 2004-12-06 2005-12-06 心筋障害又は心不全の治療もしくは予防組成物

Publications (1)

Publication Number Publication Date
ATE439141T1 true ATE439141T1 (de) 2009-08-15

Family

ID=36577914

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814479T ATE439141T1 (de) 2004-12-06 2005-12-06 Zusammensetzungen basierend auf midkine zur behandlung von chronischen ischämienreperfusionsschäden

Country Status (6)

Country Link
US (1) US9023799B2 (de)
EP (1) EP1832296B1 (de)
JP (1) JP4791770B2 (de)
AT (1) ATE439141T1 (de)
DE (1) DE602005016016D1 (de)
WO (1) WO2006062087A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5025646B2 (ja) * 2005-11-08 2012-09-12 公益財団法人先端医療振興財団 虚血性心疾患の治療方法
US8288343B2 (en) 2007-03-30 2012-10-16 National University Corporation Nagoya University Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation
US20190250172A1 (en) * 2015-11-12 2019-08-15 Celltrend Gmbh Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0827021A (ja) * 1994-07-22 1996-01-30 Mitsui Toatsu Chem Inc 医薬組成物
CA2260014A1 (en) * 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
US8106009B2 (en) * 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
WO1999016463A1 (fr) 1997-09-26 1999-04-08 Meiji Milk Products Co., Ltd. Agents preventifs ou remedes pour les maladies ischemiques
MXPA00010110A (es) * 1998-04-17 2002-08-06 Angiogenix Inc Factores angiogenicos terapeuticos y metodos para su uso.
US20050079151A1 (en) * 1998-07-10 2005-04-14 Shinya Ikematsu Therapeutic agents for apoptosis-related diseases
KR20010071798A (ko) 1998-07-10 2001-07-31 무라마쯔 다카시 세포자멸사 관련질환 치료제
JP2005068122A (ja) * 2003-08-27 2005-03-17 Mitsuru Horiba ミッドカインによる心筋障害予防および治療への応用。
US20060216709A1 (en) * 2003-12-10 2006-09-28 Carmit Levita Midkine-like protein
JP5025646B2 (ja) * 2005-11-08 2012-09-12 公益財団法人先端医療振興財団 虚血性心疾患の治療方法

Also Published As

Publication number Publication date
US9023799B2 (en) 2015-05-05
JP2006188483A (ja) 2006-07-20
EP1832296A1 (de) 2007-09-12
EP1832296A4 (de) 2008-01-16
WO2006062087A1 (ja) 2006-06-15
EP1832296B1 (de) 2009-08-12
DE602005016016D1 (de) 2009-09-24
JP4791770B2 (ja) 2011-10-12
US20100056437A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
AR112816A2 (es) Compuestos que inhiben el enlace de la proteína smac al inhibidor de proteínas de apoptosis (iap)
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
MY150531A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
DE602007007666D1 (de) Verfahren zur herstellung von nebivolol
DE602007009487D1 (de) 6-modifizierte bicyclische nukleinsäureanaloga
MA32372B1 (fr) INHIBITEURS DPP-IV à UTILISER DANS LE TRAITEMENT DE LA NAFLD
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
HK1116073A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
ATE538665T1 (de) Lipidzusammensetzung zur verbesserung der hirnfunktion
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
NO20080442L (no) Fosforamidat alkylator promedikament
PE20070723A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
MX2009013886A (es) Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
PH12016501073B1 (en) Tropomyosin-related kinase (trk) inhibitors
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
ZA200705177B (en) Lyophilization of virosomes
EP3760638A3 (de) Zusammensetzungen und verfahren unter verwendung von lysophosphatidylcholingerüsten
IN2014DN09392A (de)
DE602007010447D1 (de) Verwendung von 4,17-beta-dihydroxyandrost-4-en-3-on zur behandlung von krebs
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
DE602006017882D1 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties